搜尋
產品
社群
市場
新聞
經紀商
更多
TW
立即開始
社群
/
投資想法
/
$IDXG On The Run Again and this time it will be sustained
看多
$IDXG On The Run Again and this time it will be sustained
由StockGuild提供
關注
關注
已更新
2017年3月29日
6
2017年3月29日
Let's recap
IDXG
CC:
1. New York State and AETNA approvals of ThyraMIR®, microRNA assay
2. Talked about the Debt being restructured
3. No more offerings
4. Reduced operating costs
5. Talks of doing business with their BarreGen model
6. Talks of partnering with another bio he didn't discuss.
7. EPS value of $3.25 vs -($12.04) same quarter last year
8. Sales of $3.122 million.
9. Goldman, Rodman and Renshaw, Barclays were on the CC too big boys will be here soon enough count on it.
10. 64% of the S/S is SHORT
11. Raised $14 million in gross equity and restructured over $9.3 million of secured debt
12. Revenue increased 39%
Also most importantly the Patent Approval!!!
IDXG
European Patent Decision
data.epo.org/publication-server/pdf-document?pn=2772550&ki=B1&cc=EP
ALSO FULL YEAR HIGHLIGHTS READ HERE:
ih.advfn.com/p.php?pid=nmona&article=74215692
2017年3月29日
註釋
Alerted this on Twitter earlier in the day. Will post charts in real time next time.
BAC
breakout
Facebook (FB)
FNMA
Fundamental Analysis
IDXG
microcap
snap
technicals
TWTR
StockGuild
關注
更多:
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在
使用條款
閱讀更多資訊。